News from halozyme therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 11, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Reports Second Quarter 2014 Financial Results

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2014. Financial...

Aug 04, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme to Host second Quarter 2014 Financial Results Conference Call

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11,...

Jul 22, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial...

Jun 25, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5...

Jun 17, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the JMP Securities 2014 Healthcare Conference in New York, NY, on Tuesday,...

Jun 15, 2014, 15:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented a scientific poster highlighting the CONSISTENT 1 trial results at the 74th...

Jun 04, 2014, 16:05 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on...

May 29, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The Jefferies 2014 Global Health Care Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2014 Global Health Care Conference in New York, NY, on...

May 14, 2014, 18:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The UBS 2014 Global Health Care Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2014 Global Health Care Conference in New York, NY, on Tuesday, May...

May 12, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Reports First Quarter 2014 Financial Results

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2014. Financial...

May 07, 2014, 16:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2014 Health Care Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas,...

May 05, 2014, 17:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme to Host first Quarter 2014 Financial Results Conference Call

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2014 on Monday, May 12,...

Apr 09, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Clinical Hold of PEGPH20 Pancreatic Cancer Trial Following Voluntary Halt of Trial by Halozyme

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday...

Apr 08, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Preclinical Data Presentations At The Association Of Cancer Research Annual Meeting

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be...

Apr 04, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Temporary Halt Of Phase 2 Trial Enrollment And Dosing For PEGPH20

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that as a result of a recommendation received yesterday from an independent Data...

Apr 02, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Appointment Of Oncology Product Team Leader And Other Executive Transitions

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Sunil Joshi as Vice President and Global Product Team Lead...

Mar 31, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces that Consistent 1 Trial Of Hylenex® Recombinant Met Primary Endpoint

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the...

Mar 28, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Roche Marketing Authorization For MabThera SC For Patients With Common Forms Of Non-Hodgkin Lymphoma In European Union

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation...

Mar 25, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Positive Results From Phase 1/2 Clinical Trial In Cellulite With HTI-501

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced top-line data from a proof of concept Phase 1/2 clinical trial evaluating the use of...

Mar 05, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Therapeutics To Present At The Barclays 2014 Global Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Barclays 2014 Global Healthcare Conference in Miami, FL on March 11, 2014...